Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2019

View Archived Issues

Mouse model of 8-OH-DPAT-induced compulsive-like responses confirms the key role of 5-HT

EA-230 attenuates the systemic inflammatory response in humans

Chromatin problem linked to accelerated aging

CD40-targeting peptide KGYY-6 may ameliorate multiple sclerosis

Tuberculosis vaccine MTBVAC shows promise in phase I/II trial in adults and infants

New potent vanin-1 inhibitor as preclinical candidate for inflammatory bowel disease

FDA grants approval for Taltz as treatment of active ankylosing spondylitis

Positive topline results from pivotal phase III ORION-11 study of inclisiran

PACAP27 identified as a novel target for the treatment of migraine

IL-2-R336A fusion toxin enhances antitumor immune response in preclinical models

Esteve Pharmaceuticals describes dual CACNA2D1/mu opioid receptor ligands

New lysosomal acid glucosylceramidase inhibitors identified at Takeda

Heparegenix synthesizes new MAPKK 4 inhibitors

Janssen presents respiratory syncytial virus replication inhibitors

Ubiquitin carboxyl-terminal hydrolase 19 inhibitors discovered at Almac Discovery

Ivy, Salarius Pharmaceuticals enter collaboration to develop new cancer treatment for glioblastoma

DNA's sweet tooth linked to increased cancer risk with diabetes

Basilea completes enrollment in phase I study of oral BAL-101553 in brain cancer

New global phase IIa study evaluates tezepelumab for moderate to very severe COPD

Phase IIb CONDUCT study of cobitolimod in ulcerative colitis meets primary endpoint

ADC Therapeutics and Freenome enter biomarker collaboration for ADCT-402 program

CPRIT grant supports Emtora's development of eRapa for familial adenomatous polyposis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...